Risk Stratification for Non-Germ Cell Testicular Tumors
Non-germ cell testicular tumors (representing 5-10% of testicular neoplasms) do not use the same risk stratification system as germ cell tumors—instead, risk assessment is based primarily on histologic features and clinical behavior, with approximately 10% being malignant. 1, 2
Key Distinction from Germ Cell Tumors
The risk classification systems (good/intermediate/poor prognosis) outlined in major guidelines apply exclusively to germ cell tumors (seminomas and non-seminomatous germ cell tumors), not to non-germ cell tumors. 3
- The International Germ Cell Cancer Collaborative Group (IGCCCG) classification using AFP, β-hCG, LDH, and metastatic sites is not applicable to non-germ cell tumors 3
- Non-germ cell tumors include sex cord-stromal tumors (Leydig cell, Sertoli cell), mixed tumors, and mesenchymal/hematopoietic origin tumors 1, 2
Risk Assessment for Non-Germ Cell Tumors
For sex cord-stromal tumors (the most common non-germ cell type), risk stratification relies on histopathologic features rather than serum markers or staging systems: 2
High-Risk Features (Predicting Malignant Behavior in ~10% of Cases):
- Tumor size >5 cm 2
- Infiltrative growth pattern 2
- Increased mitotic activity (>3 mitoses per 10 high-power fields) 2
- Vascular invasion 2
- Necrosis 2
- Nuclear atypia 2
- Age >50 years at presentation 2
Low-Risk Features:
- Tumor size <5 cm 2
- Well-circumscribed margins 2
- Low mitotic activity 2
- Absence of vascular invasion 2
- Younger age at presentation 2
Clinical Approach
Since most non-germ cell tumors behave benignly, the primary assessment occurs post-orchiectomy through detailed histopathologic examination: 1, 2
- Radical inguinal orchiectomy remains the initial diagnostic and therapeutic intervention 3
- Serum tumor markers (AFP, β-hCG, LDH) are typically normal in non-germ cell tumors and should not be used for risk stratification 3
- Molecular profiling is emerging as a tool for classification and prognostication in sex cord-stromal tumors 2
Important Caveat
The malignant subset of non-germ cell tumors (~10%) does not respond to standard germ cell tumor chemotherapy regimens, making accurate histologic diagnosis and risk assessment critical for treatment planning. 2